Researchers Backpedal From Their Own Risperdal Study
11/20/2013 In the wake of the $2.2 billion settlement by Johnson & Johnson to resolve criminal and civil charges for illegal marketing of the Risperdal antipsychotic pill (more here), two of the authors of a medical paper that was used to inappropriately market the medicine are back peddling from the publication, according to The Chronicle of […]
J&J to Pay at Least $2.5 Billion to Settle Hip Lawsuits
The Wall Street Journal 2013-11-19 The Wall Street Journal reports that Johnson & Johnson has agreed to pay at least $2.5 billion to settle nearly 8,000 hip implant lawsuits In its latest multibillion-dollar legal settlement, Johnson & Johnson has agreed to pay at least $2.5 billion to resolve thousands of lawsuits filed by patients who […]
Sheller in Chronicle of Higher Education on Major Drug Fraud
The Chronicle of Higher Education 2013-11-08 Federal prosecutors on Thursday concluded another multibillion-dollar settlement with a major pharmaceutical company accused of illegally marketing its drugs. In this case, the company was Johnson & Johnson, the total payment was $2.2-billion, and the key drug was Risperdal, which was approved by federal regulators to treat schizophrenia in […]
Sheller in Philadelphia Inquirer on $2.2B Risperdal Settlement
Philadelphia Inquirer 2013-11-05 Sheller, P.C.’s representation of whistleblowers totals over $6 billion, with three of the top five pharmaceutical settlements in history: 2009: Pfizer $2.3 billion (Geodon) 2009: Eli Lilly & Co. $1.4 billion (Zyprexa) 2013: Johnson & Johnson $2.2 billion (Risperdal, Invega) and in 2010 : Astra Zeneca $520 million (Seroquel) WASHINGTON – Health-care […]
Number One in Pennsylvania for Verdicts and Settlements 2014
2014-12-19 The $2.2 Billion settlement with Johnson & Johnson Leads the Pack The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled by Sheller, P.C. with a $2.2 billion settlement over healthcare giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals. J&J paid the […]
Sheller on Lawyer Spars With FDA Over J&J Risperdal Court Documents
Pharmalot.com, Pharmaceutical Industry News 2013-07-11 In an unusual tactic, an attorney is prodding the FDA to seek documents that purportedly detail side effects caused by the Risperdal antipsychotic, but cannot be released publicly due to a court order. The documents were sealed by a Philadelphia judge as part of ongoing litigation over claims the Johnson […]
Sheller in Philadelphia Inquirer “FDA Slow to Ask J&J for Drug Data”
The Philadelphia Inquirer & “Fierce Pharma” 2013-07-10 The U.S. Food and Drug Administration is dragging its feet in addressing concerns that Johnson & Johnson’s antipsychotic drugs Risperdal and Invega are dangerous, a Philadelphia lawyer says in letters to the federal agency, and the company should allow those alleging harm from the medicines to release information […]
